ArticleObesity facts2026
The Effect of Submaximal Doses of Semaglutide on the Expression of Microribonucleic Acid in Patients with Obesity: A Pilot Study.
Article in Obesity facts, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlucagon-like peptide 1 receptor agonists (GLP-1RAs) including semaglutide have emerged as some of the most potent drugs in the treatment of obesity. This effect can be mediated by changes in the regulation of microribonucleic acid (miRNA) expression. However, currently, there are no data regarding the effect of GLP-1RA on the expression of miRNA in patients with obesity. The aim of this study was to investigate the effect of semaglutide therapy administered at submaximal doses on changes of miRNA in obese patients.
methodsThis was a pilot, prospective, observational, post-marketing study enrolling 31 adult individuals with obesity treated with semaglutide at submaximal doses. Blood samples were taken prior to and after 6 months of semaglutide administration for plasma miRNA levels. All patients received submaximal doses of semaglutide ranging from 0.25 mg to 1.5 mg once weekly.
resultsWe observed a nominally significant increase in the expression of hsa-miR-151b (Homo sapiens microRNA), hsa-miR-223-3p, hsa-miR-27b-3p, hsa-miR-29c-3p, hsa-miR-4284 and a nominally significant decrease in the expression of hsa-miR-1273f, hsa-miR-4644, hsa-miR-6071 after 6 months of semaglutide treatment. However, none of the associations remained significant after FDR correction.
conclusionOur study demonstrated a nominally significant change in the expression of 8 miRNAs after the 6-month treatment with submaximal doses of semaglutide in patients with obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.